Two siblings from consanguineous parents died perinatally with a condition characterized by generalized hypotonia, respiratory insufficiency, arthrogryposis, microcephaly, congenital brain malformations and hyperglycinemia. Catalytic activities of the mitochondrial respiratory complexes I and II were deficient in skeletal muscle, a finding suggestive of an inborn error in mitochondrial biogenesis. Homozygosity mapping identified IBA57 located in the largest homozygous region on chromosome 1 as a culprit candidate gene. IBA57 is known to be involved in the biosynthesis of mitochondrial [4Fe-4S] proteins. Sequence analysis of IBA57 revealed the homozygous mutation c.941A > C, p.Gln314Pro. Severely decreased amounts of IBA57 protein were observed in skeletal muscle and cultured skin fibroblasts from the affected subjects. HeLa cells depleted of IBA57 showed biochemical defects resembling the ones found in patient-derived cells, including a decrease in various mitochondrial [4Fe-4S] proteins and in proteins covalently linked to lipoic acid (LA), a cofactor produced by the [4Fe-4S] protein LA synthase. The defects could be complemented by wild-type IBA57 and partially by mutant IBA57. As a result of the mutation, IBA57 protein was excessively degraded, an effect ameliorated by protease inhibitors. Hence, we propose that the mutation leads to partial functional impairment of IBA57, yet the major pathogenic impact is due to its proteolytic degradation below physiologically critical levels. In conclusion, the ensuing lethal complex biochemical phenotype of a novel metabolic syndrome results from multiple Fe/S protein defects caused by a deficiency in the Fe/S cluster assembly protein IBA57. †
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INTRODUCTION
The maturation of cellular iron-sulfur (Fe/S) proteins in eukaryotes is highly complex and involves more than 25 known biogenesis factors for the de novo synthesis of Fe/S clusters and their insertion into apoproteins (1, 2) . The biosynthetic process is initiated by the mitochondrial Fe/S cluster (ISC) assembly machinery that also performs a major role in the biosynthesis of cytosolic and nuclear Fe/S proteins. Maturation of the latter class of Fe/S proteins is assisted by the cytosolic Fe/S protein assembly (CIA) machinery (3) . The components of both the ISC and CIA machineries are highly conserved from yeast to man, many of them being essential for cell viability, underscoring the vital importance of Fe/S clusters. In eukaryotic cells, essential Fe/S proteins encompass all replicative DNA polymerases (4), DNA primases, several DNA helicases (5) and the ABC protein ABCE1 required for ribosome assembly and protein translation (6) .
The mitochondrial ISC assembly machinery consists of more than 15 different proteins best studied in yeast (7) . The biogenesis pathway can be subdivided into three major steps. First, a [2Fe-2S] cluster is assembled de novo on the scaffold protein Isu1 (human ISCU). This step requires the production of sulfur from cysteine by the cysteine desulfurase complex Nfs1-Isd11 and frataxin (FXN) as a putative iron donor and/or regulator. Electron transfer mediated by the [2Fe-2S] ferredoxin (human FDX2) and ferredoxin reductase is thought to reduce sulfur to sulfide. In a second step, the [2Fe-2S] clusters are released from Isu1. Dissociation of the Fe/S clusters is facilitated by the mitochondrial Hsp70 chaperone Ssq1 (human HSPA9) and its J-type co-chaperone Jac1 (HSC20). The Fe/S cluster may be bound transiently to the monothiol glutaredoxin 5 (GLRX5) from which it is targeted in a third step to dedicated Fe/S apoproteins with the help of various ISC targeting factors. For instance, IND1 (also termed NUBPL) (8, 9) directs Fe/S clusters to respiratory complex I. NFU1 and BOLA3 deliver clusters to complex I, succinate dehydrogenase (SDH) and lipoic acid synthase (LIAS) (10, 11) . Either before or during the Fe/S clustertargeting reactions, the [2Fe-2S] cluster synthesized on Isu1 is converted into the [4Fe-4S] form by a protein complex consisting of the A-type ISC proteins Isa1 (human ISCA1), Isa2 (ISCA2) and the folate-binding protein IBA57 (12, 13 (14) . In addition, the citric acid cycle enzyme aconitase (ACO2) and LIAS contain one and two [4Fe-4S] clusters, respectively.
Phenotypically diverse disorders have been reported as the result of deficiencies in distinct ISC assembly components. In the neurodegenerative disorder Friedreich's ataxia (MIM229300), the defect in the early acting ISC protein FXN is associated with diminished function of the respiratory complexes I-III, lowered aconitase activity and mitochondrial iron accumulation (15) . In contrast, a patient with a mutation in GLRX5 presented with a sideroblastic anemia characterized by mitochondrial and cytosolic Fe/S protein defects and iron overload in mitochondria (MIM205950) (16) . A musclespecific splicing defect in the scaffold protein ISCU causes a myopathy with exercise tolerance and lactic acidosis (17, 18) . Biochemically, this is associated with cellular Fe/S protein deficiencies and altered iron homeostasis. Recently, pathogenic mutations in BOLA3 (MIM613183) and NFU1 (MIM608100) have been associated with defective Fe/S protein biosynthesis in patients presenting with respiratory chain defects, hyperglycinemia and low pyruvate dehydrogenase (PDH) complex activities (10, 11) . For these latter cases, no major effects on iron metabolism have been reported, a finding consistent with the late role of these ISC proteins in biogenesis (7) . It is still unclear how these diverse clinical phenotypes arise from the underlying molecular Fe/S protein biogenesis defects.
Here, we report the first pathogenic mutation in the ISC assembly gene IBA57 associated with a unique phenotype. Two siblings presented with a combined respiratory chain deficiency involving complex I and II, as well as defects in lipoate-containing enzymes and the citric acid cycle enzyme aconitase (ACO2). Biochemical studies in IBA57-depleted HeLa cells demonstrated that the mutated IBA57 protein is rapidly degraded, suggesting that the complex disease phenotype can be biochemically explained by the severe maturation defect of mitochondrial [4Fe-4S] proteins arising from the IBA57 functional deficiency.
RESULTS
The two siblings reported here became critically ill shortly after birth. They were born at term and were the first (P1) and second (P2) child from healthy young parents. The parents were first cousins of Moroccan origin. Prenatal ultrasound examination had shown intra-uterine growth retardation, polyhydramnios, microcephaly and an enlarged cerebral ventricle system in both siblings. Immediately after birth, P1 presented with severe hypotonia, generalized muscle weakness and absent primitive reflexes. The Apgar score was 4, 4 and 7, after 1, 5 and 10 min, respectively. His birth weight was 2580 g, length 48 cm and head circumference 30.5 cm (microcephaly). He had dysmorphic features, including retrognathia, high palate, widely spaced nipples, arthrogryposis of elbows, wrists, fingers and knees and showed signs of encephalopathy (Table 1) . In blood, a metabolic acidosis, severely increased lactate concentrations and hyperglycinemia were detected. Blood cell count, hemoglobin and hematocrit were normal (Supplementary Material, Table S1 ). CK and transaminases were normal. Cerebral MRI showed white matter abnormalities, a hypoplasia of the corpus callosum, bilateral frontoparietal polymicrogyria, hypoplasia of the medulla oblongata and cytotoxic edema of the cortex affecting the left frontal and both occipital lobes (Fig. 1) . Neonatal intensive care was started, but adequate supportive treatment was ineffective as the clinical condition further deteriorated. Intensive neonatal care was stopped at Human Molecular Genetics, 2013, Vol. 22, No. 13 2591 day six. The phenotype of neonatal hypotonia leading to early demise associated with high glycine in cerebrospinal fluid (CSF) initially pointed at the diagnosis of glycine encephalopathy due to non-ketotic hyperglycinemia. Molecular analysis of the genes coding for glycine decarboxylase (GLDC, MIM238300) and aminomethyltransferase (AMT, MIM238310), however, did not reveal any coding region mutation. More molecular genetic investigations revealed a homozygous pathogenic mutation in IBA57 that prompted effective investigations in the second sibling confirming prenatally the same homozygous mutant genotype. As the parents decided against selective interruption of the pregnancy, a girl was born at term. Her body weight was 2240 g, length 48 cm and head circumference 30.5 cm. Apgar scores were 1, 4 and 1, at 1, 5 and 10 min, respectively. She showed poor reactivity and was severely hypotonic. In accordance with the parents, only comfort therapy was provided. This patient died within the first 15 min after birth due to hypoventilation and low cardiac activity.
Based on the clinical presentation predominantly characterized by severe hypotonia associated with hyperlactacidemia, a respiratory chain defect was suspected. Spectrophotometric analysis of the respiratory chain enzymes in skeletal muscle revealed deficient catalytic activities of complexes I and II in either sibling ( Table 2 ). The activities of complex III were normal. The activity of complex IV was deficient in P2 and low normal in P1. In cultured skin fibroblasts from both patients, a significantly reduced activity for complexes II and IV was found (complex I not measured). The activity of complex III was not significantly diminished.
Activity staining of the oxidative phosphorylation (OXPHOS) complexes in the blue native-polyacrylamide gel electrophoresis (BN-PAGE) gel using mitochondria isolated from skeletal muscle confirmed the catalytic deficiency of complexes I and II in both infants ( Fig. 2A) . The activity staining for complexes III and V was comparable to that in controls. Staining for complex IV activity was only slightly decreased in both individuals. The amount of all five OXPHOS complexes was quantitated in skeletal muscle by western blotting using a mixture of specific antibodies directed against one subunit of each complex. In both siblings, severely decreased signals for complexes I, II and IV subunits were detected in skeletal muscle, whereas the signals for complexes III and V were preserved (Fig. 2B) . Together, these findings are in accordance with the spectrophotometric results ( Table 2) .
The respiratory chain defects, in combination with the clinical findings, the increased glycine levels in CSF and serum and the absence of mutations in non-ketotic hyperglycinemia genes (GLDC and AMT) generated the hypothesis that an inborn error in the ISC biosynthesis pathway may be the cause of the lethal metabolic disorder. Homozygosity mapping of P1 revealed six homozygous regions. These were screened for the presence of genes involved in ISC biosynthesis (7). One of these genes, IBA57, was present in the largest homozygous region located on chromosome 1. Mutation analysis of IBA57 revealed a homozygous mutation, (c.941A . C leading to p.Gln314Pro; ENST00000366711) in both individuals. The same mutation was identified in both parents in a heterozygous state (Fig. 3 ), but was not present in the 1000 Genomes Project (December 2011) (http://www.1000genomes.org/) or in the Exome Variant Server (http://evs.gs.washington.edu/EVS/), nor in 186 Moroccan control alleles. The Gln314 residue of IBA57 is not conserved in eukaryotes, not even in vertebrates, and is located in a non-conserved region of the protein (Supplementary Material, Fig. S1 ). For structural modeling attempts, we used Escherichia coli YgfZ and related structures as templates (19) . E. coli YgfZ and human IBA57 share a stretch of 43 residues with 42% identity, yet the remainder sequence shows hardly any conservation, particularly not in the mutated region. Nevertheless, modeling indicated that the mutated residue may be located in a loop structure close to the surface. However, depending on the template used for modeling, the location of the mutated residue differed substantially within the loop, thus, precluding any predictions on possible conformational effects of the mutation.
To verify the causal nature of the IBA57 mutation for the disease phenotype, we first analyzed the consequence of the mutation on the cellular amounts of IBA57. The protein was hardly detectable by western blotting of mitochondrial extracts from skeletal muscle and cultured skin fibroblasts of both siblings (Fig. 4A ). Immunofluorescence staining of cultured skin fibroblasts showed a severely decreased signal of IBA57 in mitochondria of both siblings when compared with control cell lines ( Fig. 5A-I ). These data support the idea that the mutation in IBA57 might be causative of the disease phenotype.
We next analyzed the amount of complex II that is a maturation target of IBA57 (12) . Immunofluorescence staining for SDHB (subunit of complex II) revealed a significant decrease in complex II in both siblings when compared with control skin fibroblasts ( Fig. 5J -R) . Because IBA57 was shown to be required for maturation of the mitochondrial Fe/S protein LIAS (12, 20) , we tested the lipoic acid (LA) content of the two mitochondrial enzymes a-ketoglutarate dehydrogenase (aKDH) and PDH (21) by western blotting using a LA-specific antibody in mitochondrial extracts isolated from skeletal muscle and cultured skin fibroblasts. A severe decrease in lipoylated proteins was found in both subjects (Fig. 4B) . Together, these results are fully compatible with the hypothesis of a mutated IBA57 being the causal agent of the disease phenotype triggering defects in mitochondrial Fe/S protein assembly. All other data are expressed as the logarithm of OXPHOS activity divided by the logarithm of citrate synthase activity (Z-score) The Z-score is calculated as the activity ratio for the patient sample minus the mean activity ratio for the control samples divided by the SD for the control samples. Control sample ratios are given as mean + SD. Deficient activities are considered when the Z-score is , -3.0. Deficient activities are shown in bold. To independently test this hypothesis, an RNAi-mediated depletion of IBA57 in human cell culture was used (12) . RNAi-treated HeLa cells were co-transfected with equal amounts of expression plasmids encoding either the wild-type IBA57 protein or IBA57 carrying the Q314P exchange. The RNAi treatment strongly depleted mitochondrial IBA57, whereas the levels of a-subunits (ATP5A1) and b-subunits (ATP5B) of mitochondrial complex V and cytosolic tubulin remained unchanged (Fig. 6A) . RNAi-treated cells co-transfected with the IBA57 expression plasmids produced similar levels of mutated IBA57_Q314P and more than 10-fold higher amounts of wild-type IBA57 when compared with endogenous protein (Fig. 6A) . Both plasmid-borne proteins were predominantly located in the mitochondriacontaining fraction.
The depletion of IBA57 was associated with significant defects in the enzyme activities of the [4Fe-4S] clustercontaining mitochondrial aconitase (ACO2, mtAco) and complex II (residual activities of 55 and 16%, respectively; Fig. 6B ). Moreover, the activity of complex IV (cytochrome c oxidase), which does not contain a Fe/S cluster, was decreased to 42% of control values. An effect of IBA57 depletion on complex IV activity has been reported previously for both yeast and human cells (12, 20) . All the monitored enzyme activities were partially restored on co-transfection with wildtype IBA57. In contrast, mutated IBA57_Q314P was hardly effective in reversing the loss in enzyme activities (Fig. 6B) .
Severe decreases in the maturation of mitochondrial Fe/S proteins are often associated with a diminution of their protein levels and likely result from degradation of the apoproteins during longer times of defective maturation. Such an effect has also been reported for depletion of IBA57 (12) . Immunostaining of IBA57-depleted cell extracts for respiratory complexes II and IV revealed a significant decrease in the latter proteins, whereas the levels of mitochondrial aconitase (ACO2) and respiratory complexes I and III were only mildly affected (Fig. 6C and Supplementary Material,  Fig. S2 ). As expected, the level of the mitochondrial [2Fe-2S] protein ferrochelatase (FECH) was not diminished by IBA57 depletion. Plasmid-assisted synthesis of wild-type IBA57 restored the depleted Fe/S protein levels efficiently. Likewise, mutant IBA57_Q314P was almost fully capable of complementing the Fe/S protein levels ( Fig. 6C and Supplementary Material, Fig. S2 ). This indicates that the mutated IBA57 protein retained some residual maturation activity and partially restored the severe Fe/S protein assembly defect. Nevertheless, the mutated protein was still unable to restore the enzyme activities indicating a partial functional impairment. We next measured the LA content of aKDH and PDH after RNAi-mediated IBA57 depletion. The strong decrease in LA content of the E2 proteins of these complexes on IBA57 depletion was fully compensated by expression of both wild-type and mutant IBA57 (Fig. 6C and Supplementary  Material, Fig. S2 ). Taken together, these findings suggest that the mutated IBA57 retained residual functionality in Fe/S protein biogenesis, a finding consistent with the non-conserved nature of the exchanged residue.
IBA57 is a late-acting protein of the ISC assembly machinery (7, 12, 20) . Hence, its functional depletion is not expected to be associated with an impact on the maturation of cytosolicnuclear Fe/S proteins and on iron homeostasis, as this is the case for members of the core ISC assembly machinery (1, 15, 16, 22) . Consistent with this expectation, hematocrit and hemoglobin parameters in Patient 1 showed no significant deviation from control values (Supplementary Material, Table S1 ). We next estimated the amounts of the cytosolic Fe/S protein glutamate phosphoribosylpyrophosphate amidotransferase (GPAT) on RNAi-mediated IBA57 depletion in HeLa cells. GPAT protein levels are a direct measure of the efficiency of cytosolic Fe/S protein biogenesis (23) . No GPAT diminution was seen on IBA57 depletion. We then tested the effects of IBA57 depletion on the activity and level of the cytosolic [4Fe-4S] cluster-containing aconitase (ACO1, cytAco) also referred to as iron regulatory protein 1 (IRP1). CytAco activity was mildly affected to 70% of control values in IBA57-depleted cells, whereas protein levels were unchanged. The slightly decreased cytAco activity could not significantly be complemented by expression of wild-type or mutant IBA57. In all likelihood, the subtle effect on cytAco activity is an indirect result of the IBA57 depletion, similar to previously observed effects for deficiencies in ISCA1 and ISCA2 (12) . Finally, we measured the level of IRP2, another key protein for regulation of iron homeostasis via post-transcriptional control of various target mRNAs. Whereas IRP1 uses its Fe/S cluster for iron sensing, IRP2 does not assemble an Fe/S cluster, yet is degraded under ironreplete conditions. Its level, therefore, is an indirect measure of cytosolic iron concentration (2) . The amount of IRP2 was not altered significantly on IBA57 depletion indicating no major change in cytosolic iron availability (Fig. 6C and Supplementary Material, Fig. S2 ). Collectively, our results show that IBA57 deficiency does not significantly affect cytosolic Fe/S protein biogenesis and cellular iron metabolism.
Because our data showed that mutated IBA57 retained some activity, we asked what may be the reason for the severe functional defects in the affected individuals. As shown above, mutant mitochondria from both affected individuals contain low amounts of IBA57 when compared with controls (Fig. 4A) . Moreover, parallel expression of wild-type and mutant IBA57 from equal amounts of plasmid led to much lower levels of mutant protein in HeLa cell culture (Fig. 6) . We, therefore, reasoned that the mutation might lead to proteolytic sensitivity of IBA57 and a protein decay below functionally critical levels. We, therefore, tested the effect of membrane-permeable protease inhibitors on the levels of a myc-tagged version of mutant IBA57_Q314P. Addition of Pefabloc or MG132, which are known to inhibit the major mitochondrial matrix protease PIM1 (24) , largely increased the levels of IBA57_Q314P-myc in a time-and inhibitor concentration-dependent fashion (Fig. 7A) . In contrast, endogenous, nuclear-encoded IBA57 was unaffected. This result clearly indicated that IBA57_Q314P is susceptible to proteolysis and can be stabilized by addition of protease inhibitors, whereas the wild-type protein apparently has a low turnover rate.
We finally tested whether the increased levels of mutated IBA57_Q314P in the presence of Pefabloc may influence the efficiency of Fe/S protein maturation. To this end, we performed the RNAi-mediated depletion and complementation experiment described in Figure 6 in the presence of Pefabloc for 16 h that yields a 3-fold higher level when compared with endogenous IBA57. The activity of respiratory complex II was restored to almost control levels (Fig. 7B) . Activities of mitochondrial aconitase (ACO2) and respiratory complex IV were only slightly improved by addition of Pefabloc. As seen above, the diminished levels of complex II subunits and the LA content of aKDH and PDH subunits were restored on production of wild-type and mutant IBA57 and in the presence of Pefabloc (Supplementary Material, Fig. S3 ). Taken together, these findings clearly indicate that the mutated IBA57 retains some, but not full functionality. Importantly, the mutated protein is highly sensitive to proteolysis and, thus, may be degraded in affected individuals below functionally critical levels.
DISCUSSION
Our report shows that a homozygous mutant genotype in IBA57 causes a metabolic syndrome apparent before birth and lethal in early infancy. Besides immediately apparent components, including hypotonia, respiratory insufficiency and congenital microcephaly, the syndrome is also characterized by hyperglycinemia and brain malformations (Table 1 ; Fig. 1 ). Parental consanguinity and double occurrence of the Immunoblot of mitochondrial proteins isolated from skeletal muscle and cultured skin fibroblasts from both individuals shows a severely reduced signal for IBA57 protein, below 25% of the control sample. Antibodies against complex V subunit alpha (ATP5A1) were used as loading control. With this antibody, two additional bands were detected. (B) Immunoblot using antibodies against lipoylated residues in skeletal muscle and cultured skin fibroblast mitochondrial extracts. Both individuals showed a severely reduced signal for the bands corresponding to the lipoylated residues PDH-E2 and aKDH-E2. Antibodies against porin were used as loading control.
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Human Molecular Genetics, 2013, Vol. 22, No. 13 disorder in the sibship show that the mode of inheritance is autosomal recessive and implies a one in four probability of recurrence in the family. The clinical picture of the probands presented here resembles that of three siblings with NFU1 defect, designated as multiple mitochondrial dysfunction syndrome 1 (MMDS1, MIM605711) (10). These NFU1-deficient infants presented with feeding difficulties, muscular weakness, respiratory insufficiency, lethargy and lack of responsiveness from the first days of life and died within the first month of life. Navarro-Sastre et al. reported 10 more infants with NFU1 mutations with a slightly less severe phenotype. So far, only one boy was reported with a genetic defect in BOLA3 designated as MMDS2 (MIM614299) (10) . The latter patient presented with signs of encephalopathy at the age of 4 months and succumbed at the age of 11 months. The biochemical profile of individuals with defects in IBA57 is both similar to and distinct from that reported for functional deficiencies in NFU1 or BOLA3 (10, 11) . IBA57 defects are associated with a general mitochondrial [4Fe-4S] protein defect, including respiratory complexes I and II, aconitase and LIAS. Functional impairment of the latter enzyme in turn explains the increase in glycine in serum and CSF, as seen in the probands presented here and in the individuals with pathogenic mutations in NFU1 and BOLA3. In contrast, mutations in NFU1 and BOLA3 do not affect the [4Fe-4S] protein aconitase. This has prompted the model of IBA57 assisting the generation of [4Fe-4S] clusters while NFU1 and BOLA3 serve as specific ISC targeting factors (7) . The biochemical phenotypes of mutations in IBA57, NFU1 and BOLA3 differ characteristically from mutations in FXN, GLRX5 and ISCU (15) (16) (17) (18) . Cells defective in these core ISC machinery proteins show, in addition to general mitochondrial [2Fe-2S] and [4Fe-4S] protein defects, a strong impairment in cytosolic Fe/S protein maturation and a severe cellular iron accumulation as a consequence of diminished IRP1 maturation and hence activation of its iron-responsive element binding. These latter effects are not seen in individuals with mutations in IBA57, NFU1 and BOLA3. Thus, these observations fit well with the current view of IBA57, NFU1 and BOLA3 serving as late-acting components of the mitochondrial ISC assembly machinery lacking a detectable maturation function for mitochondrial [2Fe-2S] and extra-mitochondrial Fe/S proteins, as well as for cellular iron regulation, thus distinguishing these components from the core ISC members (1,7) . Notably, most ISC biosynthesis defects are associated with a severe combined catalytic impairment of complexes I and II. For many mitochondrial diseases, this is an unusual finding, as in most combined OXPHOS deficiencies, nucleus-encoded complex II is functionally preserved, yet a defect of complexes I and IV is seen. These effects are caused either by mutations in the mitochondrial DNA, or, more rarely, by mutations in nuclear genes encoding mitochondrial transcription or translation factors. Altogether, these characteristic features may help in phenotypically identifying new ISC biosynthesis defects.
The mutation in IBA57 reported here may have an impact on the protein stability. Structural modeling indicated that the mutated residue may lie in a loop at the surface of the protein. In fact, western blotting and immunofluorescence experiments found the protein to be severely decreased in patient-derived mitochondria. Moreover, gene expression Figure 6 . Mutated IBA57_Q314P partially restores the functional defects of IBA57-deficient cells. HeLa cells were transfected thrice at a 3 day interval with siRNA against the mRNA of IBA57 (siIBA57) and with plasmids encoding wild-type or mutant IBA57 (IBA57_Q314P), or with the control vector pEGFP-N1. (A) After the third transfection (9 days of growth), cells were harvested, fractionated by digitonin treatment and centrifugation at 15 000g into a soluble (cytosol) and a membrane fraction containing mitochondria. Proteins were analyzed by SDS PAGE and western blotting using an antibody against IBA57, the a/b subunits of respiratory complex V (ATP5A1 and ATP5B) and tubulin. The plasmid-borne expression yielded more than 10-fold higher levels when compared with endogenous IBA57 protein while synthesis of IBA57_Q314P generated similar amounts of IBA57 as control cells. (B) The cell fractions from part A were analyzed for the enzyme activities of mitochondrial aconitase (ACO2, mtAco), respiratory complexes II and IV and cytosolic aconitase (ACO1, cytAco, IRP1). Values are given relative to the activity of mitochondrial citrate synthase or cytosolic lactate dehydrogenase and are normalized to the ratios for control cells. Data are presented as mean + SD (n ¼ 4). (C) Cell extracts were subjected to SDS PAGE and western blotting using antibodies against the indicated proteins. The LA-containing PDH-E2 and aKDH-E2 subunits of mitochondrial PDH and aKDH were visualized by immunostaining against LA. A representative result is shown.
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Human Molecular Genetics, 2013, Vol. 22, No. 13 studies in HeLa cells showed that the levels of mutated IBA57 protein were significantly lower than the wild-type copy. Thus, the mutation mainly affects IBA57 protein stability leading to rapid degradation. This conclusion was strongly supported by inhibition of the mitochondrial protease PIM1 in HeLa cells that substantially increased the amount of mutant IBA57. The elevated amounts of IBA57 were still unable to fully restore the activity of ISC-dependent enzymes, yet the protein was partially functional as deduced from the regeneration of wild-type levels of affected Fe/S proteins. Such an effect, i.e. decreased Fe/S protein activity, but not yet diminished levels of apoproteins, is usually seen on less severe impairment of the maturation pathway. In conclusion, the major disease-causing effect may arise from the degradation of IBA57 below physiologically critical amounts, rather than from a complete dysfunction of the altered IBA57 protein.
IBA57 has been shown to play an important role in Fe/S protein biogenesis in yeast (20) . In E. coli, suppression of an IBA57-related protein (named YgfZ) resulted in deficiency in some Fe/S proteins, including SDH (25) . In IBA57-depleted HeLa cells, steady-state levels of several ISC proteins were affected, including subunits of complex I (NDUFA9, NDUFA13, NDUFB4 and NDUFS3), complex II (SDH) and complex IV (MT-CO2) (12) . Catalytic activities of complex I and II were compromised. These results correlate well with the diminished activities and levels of several Fe/S proteins tested in our individuals. Notably, the activity of the [2Fe-2S] cluster-containing complex III was not affected in these individuals consistent with the previously suggested lack of function of IBA57 in [2Fe-2S] cluster formation (12, 20) .
A rather surprising finding was that in IBA57-deficient mitochondria from the two siblings also complex IV was severely decreased, although this complex does not contain any ISC-carrying subunits. However, this result is not unexpected because lowered COX2 steady-state levels have been reported in Isa protein-depleted yeast cells (13) and in ISCA or IBA57-depleted HeLa cells (12) . Such adverse effects are not due to compromised heme biosynthesis (12, 26) and are unlikely to be caused by impaired heme A production. The latter pathway depends on the [2Fe-2S] ferredoxin that is unaffected during maturation in Isa-Iba57-deficient yeast cells and possibly also in human cells (13, 22) . Why complex IV is affected on loss of ISCA-IBA57 function remains unknown at present. The failure to assemble complex I does not provide a reasonable explanation because normal complex IV activities were found in complex I assembly defects caused by depletion of IND1 (9) .
Defects in the ISC biosynthesis pathway not only have a negative effect on the respiratory complexes but also on LA-containing proteins, likely as a result of a defect in the maturation of the [4Fe-4S] protein LIAS. Pathogenic mutations in BOLA3 and NFU1 (10,11) have been shown to be associated with decreased amounts of proteins carrying a LA residue. LA is required exclusively in mitochondria. In human cells, four mitochondrial proteins bear a LA residue. They include the E2 components of PDH complex (PDH-E2), a-KDH, a branched-chain keto acid dehydrogenase (BCKDH) and the H protein of the glycine cleavage system (H-GCS). BCKDH and H-GCS are expressed mainly in liver (27, 28) , the reason why these proteins cannot be demonstrated in normal cultured skin fibroblasts or in normal skeletal muscle. A defect in the glycine cleavage system explains the increase in the glycine concentrations in the affected individuals. Earlier studies in yeast have shown that Iba57 plays a role in the maturation of [4Fe-4S] cluster-bearing radical S-adenosyl-l-methionine enzymes, including LIAS (20) . In the two siblings presented, the lipoylated groups in PDH-E2 and a-KDH-E2 were significantly decreased in mitochondrial proteins isolated from cultured skin fibroblasts and skeletal muscle tissue.
In conclusion, the genetic and biochemical analyses in the two siblings studied here show that the molecular cause of the pathogenic defects is a homozygous mutation in IBA57, a gene that codes for a protein involved in biosynthesis of mitochondrial [4Fe-4S] proteins. The mutation leads to an IBA57 protein that is partially functionally impaired and additionally is effectively degraded below physiologically relevant amounts.
MATERIALS AND METHODS

Spectrophotometric analysis
Spectrophotometric analysis was used for measurement of the catalytic activities of citrate synthase, lactate dehydrogenase Figure 7 . Mutated IBA57_Q314P is sensitive to proteolysis, yet partially functional. (A) HeLa cells were transfected with either a plasmid encoding myctagged mutant IBA57 (IBA57_Q314P-myc) or with the control vector pEGFP-N1. Cells were grown for 3 days. As indicated, the protease inhibitors Pefabloc and MG132 were added 6 h or 16 h before harvesting. Cell extracts were analyzed for IBA57 or IBA57_Q314P-myc by western blotting using an IBA57-specific antibody. (B) HeLa cells were transfected, grown and analyzed as in Figure 6 . After 8 days, 0.8 mM Pefabloc was added to one set of cells expressing IBA57_Q314P, and cells were harvested 16 h later. Mitochondriacontaining fractions were analyzed for the enzyme activities of mitochondrial aconitase (ACO2, mtAco) and respiratory complexes II and IV relative to the activity of citrate synthase. and the mitochondrial respiratory complexes in skeletal muscle (complexes I, II, II + III, III and IV), cultured skin fibroblasts (complexes II, II + III, III and IV) and HeLa cells (complexes II and IV). For the latter, also aconitase was measured. Analyses were performed according to previously described methods (29) (30) (31) (32) (33) (34) (35) (36) (37) .
In-gel activity staining following separation of respiratory complexes by BN-PAGE BN-PAGE was used to separate and visualize the respiratory complexes in mitochondria isolated from skeletal muscle. Solubilization of the complexes, BN-PAGE and staining of their catalytic activities in the gel were performed as reported earlier (38) . Patient and control samples were loaded in duplicate using equal amounts of mitochondrial protein (50 mg).
Mitotracker and immunofluorescent staining
Skin fibroblasts grown onto glass chamber slides were incubated with 25 ng/ml Mitotracker red CMXRos (Invitrogen) for 45 min at 378C. Subsequently, they were fixed in 3.5% paraformaldehyde for 15 min at 378C and permeabilized for 3 min in ice-cold acetone. Slides were rehydrated in phosphate-buffered saline (PBS) and subsequently blocked with 5% bovine serum albumin in PBS for 30 min. Slides were incubated with monoclonal antibodies directed against OXPHOS complex II subunit SDHB (MS203, 20 mg/ml) and rabbit polyclonal anti-IBA57 (crude rabbit serum, diluted 1 of 10), for 3 h at room temperature. Appropriate secondary antibodies labeled with AlexaFluor488 (Invitrogen) were added and slides were washed with PBS in between incubations. Slides were mounted with vectashield containing 4 ′ ,6-diamidino-2-phenylindole (Vector, Burlingame, CA, USA) and evaluated under a fluorescence microscope (Carl Zeiss, Göttingen, Germany).
Western blot analysis
Mitochondrial fractions were isolated from skeletal muscle and cultured skin fibroblasts. Proteins were solubilized and subsequently separated by tricine SDS PAGE. Western blotting was performed using a mixture of antibodies directed against one subunit in each of the five respiratory complexes: NDUFB8 for complex I, SDHB for complex II, core2 for complex III (UQCRC2), MT-CO2 for complex IV and subunit alpha for complex V (ATP5A1) (MS601 -360 MitoProfile w human total OXPHOS complexes detection kit, 1.5 mg/ml, MitoSciences, OR, USA). For visualization of IBA57 protein, a polyclonal antibody was raised in rabbits by injection of recombinant IBA57 purified from E. coli (12) . LA-containing proteins were detected by western blotting using an antibody against protein-bound LA (ab58724, 1 of7500, Abcam, Cambridge, UK) (20, 21) . Detection was achieved by the use of the ECL Plus TM enhanced chemiluminescence kit (GE Healthcare, Diegem, Belgium), as described previously (39) . A ChemiDoc charge-coupled device camera was used to capture the signals that were processed using Quantity Onew software (Bio-Rad, Nazareth, Belgium). HeLa cell extracts were analyzed using the following antibodies: NDUFA9 for complex I, SDHB for Complex II (both from MitoSciences, USA), UQCRFS1 for Complex III, MT-CO2 for complex IV and ATP5A1 for complex V (gift from Schägger H. and Wittig I.), ACO2 (Thermo Scientific), tubulin (clone DM1A; Sigma-Aldrich, St. Louis, MO, USA), LA (Calbiochem, La Jolla, CA, USA), FECH (gift from Dailey H.A. and T.), GPAT (gift from Puccio H.) and IRP1 and IRP2 (gift from Eisenstein R.).
Homozygosity mapping
Single-nucleotide polymorphism genotyping was performed using the Illumina HumanCytoSNP-12v2.0 BeadChip (Illumina Inc., San Diego, CA, USA). The chip was scanned on an iSCAN system, and image data were normalized using the genotyping module from the GenomeStudio analysis software according to the protocol provided by the manufacturer (Illumina Inc.). Homozygous regions were determined with the VanillaICE algorithm (40) that has been incorporated in our analysis platform CNV-WebStore (41) . All data were mapped using Human Genome Build hg19.
Mutation analysis
DNA was extracted from the parents and neonates using standard procedures. PCR reactions were carried out using primers and conditions described in Supplementary Material, Table S2 . All PCR products were purified using alkaline phosphatase (Roche, 20 U/ml) and exonuclease I (New England Biolabs, 20 000 U/ml) to remove excess dNTPs and primers. Subsequent sequencing of the PCR products was carried out using the Big Dye Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems). Products were separated on an ABI 3130XL Genetic Analyzer (Applied Biosystems). Sequence variants were identified based on IBA57 transcript ENST00000366711 for reference using the first nucleotide of the start codon (ATG) as position +1.
Site-directed in vitro mutagenesis
Site-directed in vitro mutagenesis was carried out to introduce the c.941 A . C mutation into the commercially available myc-DDK tagged human IBA57 cDNA clone (RC211947, Origene). Primers were designed using the Quickchange Primer design tool (eResources, Agilent Technologies; Supplementary Material, Table S3 ), and the site-directed in vitro mutagenesis reaction was carried out using 27.5 ng of IBA57 cDNA template, according to the manufacturer's instructions (Lightning Quickchange Site directed mutagenesis Kit, Agilent Technologies). The respective inserts were completely sequenced. Details on the sequencing primers are provided in Supplementary Material, Table S4 .
Human cell culture studies and RNAi-mediated depletion of IBA57
Human cervix carcinoma cells (HeLa) were cultured and transfected as described previously (42) . For transfection, 7.5 × 10 6 cells were resuspended in 580 ml of transfection buffer, supplemented with 1.5 nM of a small interfering RNA
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(siRNA) and 5 -10 mg of expression vectors and transfected by electroporation. After 3 days, cells were harvested, re-transfected and grown for another 3 days (12, 42) . This was repeated once more to intensify the phenotype. Expression of IBA57 was suppressed by a siRNA targeting the IBA57 mRNA at the 3 ′ untranslated region (5 ′ -AGCUCUAU GUUUCAGGGCA-3 ′ ) purchased from Life Technologies (12) . For complementation experiments, pCMV6-IBA57_ Q314P-myc was subcloned into IBA57-pEGFP-N3 (12) via BglII and BstXI restriction sites to remove the myc-tag. The relative functionality of mutated and wild-type IBA57 was tested by co-transfecting a subset of RNAi-treated cells with equal amounts of expression plasmids encoding either IBA57 carrying the patient mutation at position 314 (IBA57_Q314P) or wild-type IBA57. All cells were then fractionated by digitonin treatment into a soluble fraction containing cytosolic proteins and a membrane fraction containing mitochondria. For inhibition of proteases, transfected cells were treated with either Pefabloc (Carl Roth) or MG132 (Calbiochem) for 16 h before harvest.
